Shanghai Shenlian Biomedical Corporation, established in June 2001 with a registered capital of 410.64 million RMB, is a high-tech enterprise specializing in the research, development,production, and sales of veterinary biological products. The headqarter is based in Shanghai.

In October 2019, the company was successfully listed on the Shanghai Stock Exchange's STAR Market with the stock code 688098.

The company's main business covers the research, production, and sales of veterinary
preventive biological products and veterinary diagnostic products. It has two GMP production facilities in Shanghai and Lanzhou and is a designated enterprise for foot-and-mouth disease (FMD) vaccines by the Chinese Ministry of Agriculture and Rural Affairs. The company focuses on diseases that threaten the safety of the breeding industry and have a high demand for vaccines.The products on the market include vaccines for swine FMD and porcine circovirus (PCV), and diagnostic reagents for FMD and African swine fever (ASF). It is also developing other animal vaccines and veterinary diagnostic products.